At this year’s ESMO (October 7th -11th) in Copenhagen, the GermanOncology presented the following posters:

Final analysis of patient-reported-outcomes (PRO) and early intervention to toxicities as tools for improving compliance of patients with metastatic colorectal cancer (mCRC) treated with aflibercept+FOLFIRI (A-FOLFIRI) under real-world-conditions in Germany

Economic burden of cancer-associated thrombosis in Germany